<?xml version="1.0" encoding="utf-8" standalone="yes"?><rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom"><channel><title>VRTX on Deep Analyst AI</title><link>https://deepanalyst.ai/tags/VRTX/</link><description>Recent content in VRTX on Deep Analyst AI</description><generator>Hugo -- gohugo.io</generator><language>en-us</language><lastBuildDate>Thu, 12 Feb 2026 00:00:00 +0000</lastBuildDate><atom:link href="https://deepanalyst.ai/tags/VRTX/rss.xml" rel="self" type="application/rss+xml"/><item><title>Vertex Pharmaceuticals: The Only "Loyal Monopoly" Worth Buying Forever</title><link>https://deepanalyst.ai/posts/2026/02/vrtx-vertex-pharmaceuticals-only-loyal-monopoly-worth-buying-forever/</link><pubDate>Thu, 12 Feb 2026 00:00:00 +0000</pubDate><guid>https://deepanalyst.ai/posts/2026/02/vrtx-vertex-pharmaceuticals-only-loyal-monopoly-worth-buying-forever/</guid><description>Vertex Pharmaceuticals: The Only &amp;ldquo;Loyal Monopoly&amp;rdquo; Worth Buying Forever Monopolies are usually treated like uninvited guests at a wedding—everyone hates them, and eventually, the Department of Justice escorts them out. But Vertex Pharmaceuticals (VRTX) has built the rarest of economic castles: the &amp;ldquo;benevolent&amp;rdquo; monopoly. While the rest of the biotech sector is gambling on weight-loss fads like golden retrievers chasing a tennis ball, Vertex has quietly turned the Cystic Fibrosis (CF) market into its own private country club, and they aren&amp;rsquo;t accepting guest passes.</description></item></channel></rss>